Leerink Partners Boosts Cardinal Health (NYSE:CAH) Price Target to $187.00

Key Points

• Leerink Partners raised its price target for Cardinal Health from $186.00 to $187.00, indicating a potential upside of 20.84% from the current stock price with an "outperform" rating.
• The company reported a quarterly earnings of $2.08 EPS, surpassing analysts’ expectations by $0.05, with a revenue of $60.16 billion.
• Insiders have sold a significant amount of stock recently, with CEO Stephen M. Mason selling over 41,000 shares, representing a 61.45% decrease in his position.

Cardinal Health (NYSE:CAH - Get Free Report) had its target price raised by equities researchers at Leerink Partners from $186.00 to $187.00 in a report released on Monday,MarketScreener reports. The firm currently has an "outperform" rating on the stock. Leerink Partners' price objective suggests a potential upside of 20.84% from the stock's current price.

Other equities analysts have also issued research reports about the company. Weiss Ratings reaffirmed a "buy (b)" rating on shares of Cardinal Health in a research note on Saturday, September 27th. Wall Street Zen cut Cardinal Health from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 2nd. Jefferies Financial Group set a $150.00 target price on Cardinal Health in a research report on Tuesday, August 12th. Citigroup reiterated a "neutral" rating and issued a $170.00 price target (up from $157.00) on shares of Cardinal Health in a report on Friday, June 13th. Finally, Robert W. Baird lifted their price target on shares of Cardinal Health from $197.00 to $203.00 and gave the company an "outperform" rating in a report on Wednesday, August 13th. Twelve analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $166.00.

Cardinal Health Stock Up 0.2%

NYSE:CAH opened at $154.76 on Monday. The company's 50 day moving average price is $152.07 and its 200-day moving average price is $150.50. Cardinal Health has a 52 week low of $106.98 and a 52 week high of $168.44. The stock has a market cap of $36.77 billion, a price-to-earnings ratio of 24.01, a PEG ratio of 1.31 and a beta of 0.71.

Cardinal Health (NYSE:CAH - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported $2.08 EPS for the quarter, topping analysts' consensus estimates of $2.03 by $0.05. Cardinal Health had a net margin of 0.70% and a negative return on equity of 74.45%. The business had revenue of $60.16 billion during the quarter, compared to the consensus estimate of $60.91 billion. During the same quarter in the previous year, the firm posted $1.84 EPS. The firm's revenue was up .5% on a year-over-year basis. Cardinal Health has set its FY 2026 guidance at 9.300-9.500 EPS. As a group, sell-side analysts anticipate that Cardinal Health will post 7.95 earnings per share for the current year.

Insider Buying and Selling

In other Cardinal Health news, CEO Stephen M. Mason sold 41,575 shares of the business's stock in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $148.82, for a total value of $6,187,191.50. Following the completion of the sale, the chief executive officer directly owned 26,085 shares of the company's stock, valued at $3,881,969.70. The trade was a 61.45% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Ola M. Snow sold 28,151 shares of the company's stock in a transaction that occurred on Tuesday, August 19th. The stock was sold at an average price of $148.94, for a total transaction of $4,192,809.94. Following the completion of the sale, the insider directly owned 15,431 shares of the company's stock, valued at $2,298,293.14. The trade was a 64.59% decrease in their position. The disclosure for this sale can be found here. Insiders sold 271,676 shares of company stock worth $40,489,525 over the last 90 days. Corporate insiders own 0.12% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Greykasell Wealth Strategies Inc. bought a new position in shares of Cardinal Health during the 1st quarter worth approximately $26,000. Jones Financial Companies Lllp raised its stake in shares of Cardinal Health by 198.3% during the 1st quarter. Jones Financial Companies Lllp now owns 21,112 shares of the company's stock worth $27,000 after acquiring an additional 14,034 shares in the last quarter. Atlantic Edge Private Wealth Management LLC raised its stake in shares of Cardinal Health by 75.0% during the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 175 shares of the company's stock worth $29,000 after acquiring an additional 75 shares in the last quarter. Vermillion & White Wealth Management Group LLC increased its stake in Cardinal Health by 55.0% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 200 shares of the company's stock valued at $34,000 after purchasing an additional 71 shares in the last quarter. Finally, NewSquare Capital LLC increased its stake in Cardinal Health by 100.0% during the 2nd quarter. NewSquare Capital LLC now owns 214 shares of the company's stock valued at $36,000 after purchasing an additional 107 shares in the last quarter. Institutional investors own 87.17% of the company's stock.

Cardinal Health Company Profile

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.